# NIH Awards Tempo Therapeutics SBIR Grant

Tempo Therapeutics, a regenerative medicine company based in San Diego, California, has been awarded a **$2.25 million Small Business Innovation Research (SBIR) grant** by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support a randomized clinical study of its MAP™ Wound Matrix technology. This two-year grant aims to advance clinical development focused on improving complex wound healing, particularly for wounds involving exposed bone after non-melanoma skin cancer resection. The funding enables Tempo to accelerate clinical validation and regulatory progress without equity dilution, highlighting a significant government investment in innovative synthetic biomaterials for wound care.

- **Why this matters:** This grant signals federal support for advanced regenerative medicine technologies, creating opportunities for contractors and healthcare technology firms specializing in clinical research, biomaterials, and wound management solutions.
- Procurement professionals should note the involvement of NIH/NCI as key funding agencies prioritizing innovation in complex wound treatment.
- Companies in the biomedical and clinical trial sectors can leverage this development to align with emerging government priorities in healthcare innovation and regenerative therapies.
- The San Diego location underscores regional innovation hubs that procurement teams may consider for partnership or subcontracting opportunities.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** September 23, 2026

### Government Entities
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)

### Vendors
- Tempo Therapeutics, Inc. (awardee)

### Key Quotes
> This award brings Tempo closer to an important value-enhancing milestone: demonstrating that MAP can provide a fundamentally different approach to wound management by accelerating the formation of healthy tissue while minimizing the inflammatory foreign-body response.
> — Steven Sands, Chairman

### Sources
- [Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing](https://www.prnewswire.com/news-releases/tempo-therapeutics-awarded-2-25-million-nih-sbir-grant-to-advance-map-technology-for-complex-wound-healing-302886973.html) - PR Newswire
- [Tempo Therapeutics lands $2.3M SBIR grant for wound-healing tech | Dealroom.co](https://app.dealroom.co/news/note/tempo-therapeutics-lands-2-3m-sbir-grant-for-wound-healing-tech) - Dealroom
- [Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing - BioSpace](https://www.biospace.com/press-releases/tempo-therapeutics-awarded-2-25-million-nih-sbir-grant-to-advance-map-technology-for-complex-wound-healing) - BioSpace